Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-07-15 Board/Management Inform…
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The content focuses on an amendment to the company's bylaws, specifically updating the definition of a quorum of shareholders. There is no financial data, earnings information, or detailed report content. The document is short (3280 characters) and primarily announces a change in corporate governance documents (bylaws). This fits best under Board/Management Information (MANG) as it relates to amendments to corporate governance documents and board actions. It is not an Annual Report, Earnings Release, or Regulatory Filing of a different nature. Therefore, the classification is MANG with high confidence.
2021-07-15 English
FORM 10-Q
Interim / Quarterly Report Q3 2021
2021-07-12 English
DEF A14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, specifically labeled as "Definitive Additional Materials" related to a proxy statement for the Annual Meeting of Stockholders. It discusses voting instructions and urges shareholders to vote due to an adjourned meeting caused by lack of quorum. The content is focused on soliciting votes and providing additional proxy materials rather than the proxy statement itself or the voting results. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 3695 characters, which is consistent with a solicitation letter rather than a full proxy statement or voting results announcement.
2021-06-22 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2021-05-07 English
FORM 4
Director's Dealing
2021-04-20 English
FORM 10-Q
Interim / Quarterly Report Q2 2021
2021-04-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.